JP2013535220A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535220A5
JP2013535220A5 JP2013524130A JP2013524130A JP2013535220A5 JP 2013535220 A5 JP2013535220 A5 JP 2013535220A5 JP 2013524130 A JP2013524130 A JP 2013524130A JP 2013524130 A JP2013524130 A JP 2013524130A JP 2013535220 A5 JP2013535220 A5 JP 2013535220A5
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
preparing
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013524130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535220A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/046797 external-priority patent/WO2012019123A1/en
Publication of JP2013535220A publication Critical patent/JP2013535220A/ja
Publication of JP2013535220A5 publication Critical patent/JP2013535220A5/ja
Ceased legal-status Critical Current

Links

JP2013524130A 2010-08-06 2011-08-05 ツブリシンを調製するためのプロセス Ceased JP2013535220A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37143310P 2010-08-06 2010-08-06
US61/371,433 2010-08-06
PCT/US2011/046797 WO2012019123A1 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Publications (2)

Publication Number Publication Date
JP2013535220A JP2013535220A (ja) 2013-09-12
JP2013535220A5 true JP2013535220A5 (enExample) 2014-10-16

Family

ID=45559842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524130A Ceased JP2013535220A (ja) 2010-08-06 2011-08-05 ツブリシンを調製するためのプロセス

Country Status (12)

Country Link
US (3) US8889880B2 (enExample)
EP (1) EP2600866A4 (enExample)
JP (1) JP2013535220A (enExample)
KR (1) KR20130096712A (enExample)
CN (1) CN103140227B (enExample)
AU (1) AU2011285532B2 (enExample)
BR (1) BR112013003004A2 (enExample)
CA (1) CA2807511A1 (enExample)
EA (1) EA025471B1 (enExample)
MX (1) MX2013001402A (enExample)
SG (1) SG187728A1 (enExample)
WO (1) WO2012019123A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2489372A3 (en) 2007-03-14 2013-01-02 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
RU2523909C2 (ru) 2007-06-25 2014-07-27 Эндосайт, Инк. Конъюгаты, содержащие гидрофильные спейсеры линкеров
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
AU2011285532B2 (en) 2010-08-06 2015-09-10 Endocyte, Inc. Processes for preparing tubulysins
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (enExample) 2012-10-16 2015-10-16 Endocyte Inc
KR102575825B1 (ko) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
EP3099681B1 (en) 2014-01-28 2020-12-09 TUBE Pharmaceuticals GmbH Cytotoxic tubulysin compounds and conjugates thereof
TW201542594A (zh) 2014-04-11 2015-11-16 Medimmune Llc 雙特異性her2抗體
EP3200829B1 (en) 2014-10-01 2023-12-06 Medimmune, LLC Method of conjugating a polypeptide
SG11201706820RA (en) 2015-02-25 2017-09-28 Univ Rice William M Desacetoxytubulysin h and analogs thereof
CA3003468C (en) 2015-11-10 2024-06-18 Medimmune, Llc Binding molecules specific for asct2 and uses thereof
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
RU2018128784A (ru) 2016-01-27 2020-02-27 МЕДИММЬЮН, ЭлЭлСи Способы получения антител с заданным профилем гликозилирования
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
JP7150820B2 (ja) 2017-08-01 2022-10-11 メディミューン,エルエルシー Bcmaモノクローナル抗体薬剤コンジュゲート
WO2019108685A1 (en) 2017-11-29 2019-06-06 William March Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
AR123480A1 (es) 2020-09-11 2022-12-07 Medimmune Ltd Moléculas de unión terapéuticas
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
JP2024544520A (ja) 2021-11-10 2024-12-03 アストラゼネカ・アクチエボラーグ 抗体分子及び複合体
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
KR20250148670A (ko) 2023-02-16 2025-10-14 아스트라제네카 아베 치료용 결합 분자를 사용한 암 치료를 위한 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
DE10254439A1 (de) * 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
TWI367096B (en) 2003-01-27 2012-07-01 Endocyte Inc Vitamin-receptor binding drug delivery conjugates and pharmaceutical compositions
EP2489372A3 (en) 2007-03-14 2013-01-02 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
DE102009032972A1 (de) 2009-07-14 2011-01-20 Erbe Elektromedizin Gmbh Vorrichtung zur Herstellung von Anastomosen
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
AU2011285532B2 (en) * 2010-08-06 2015-09-10 Endocyte, Inc. Processes for preparing tubulysins

Similar Documents

Publication Publication Date Title
JP2013535220A5 (enExample)
JP2012526842A5 (enExample)
JP2010510976A5 (enExample)
UA109883C2 (uk) Спосіб отримання сполук для застосування як інгібіторів sglt2
EP4328223A3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
JP2009143956A5 (enExample)
EP3051350A3 (en) Alcoholic compound and method for producing alcoholic compound
CA2679925A1 (en) Method for producing high-purity prasugrel hydrochloride
RU2015118572A (ru) Получение и составление композиции, содержащей ингибитор мек
JP2009263394A5 (enExample)
JP2010536766A5 (enExample)
CA2796872A1 (en) Novel synthesis for thiazolidinedione compounds
EP4230631A3 (en) Process for making trisubstituted silyloxyethyl triflates
EP3388426A3 (en) Compounds for protection of cells
JP2015518473A5 (enExample)
JP2014526533A5 (enExample)
JP2016537382A5 (enExample)
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
RU2017144050A (ru) Способ синтеза производных рапамицина
RU2012128887A (ru) Способ получения гидрохлорида моксифлоксацина и его промежуточных продуктов
JP2013505206A5 (enExample)
JP2011526896A5 (enExample)
JP2012503653A5 (enExample)
JP2008517965A5 (enExample)
JP2013522207A5 (enExample)